Healthy London Partnership > Our work > Cancer > Personalised cancer care > Stable prostate cancer follow up in primary care

Stable prostate cancer follow up in primary care

Guidance and resources to support the commissioning and implementation of a holistic, primary care follow up pathway for men with stable prostate cancer.

Primary care led follow up for men with stable prostate cancer – the case for change

In 2019, the National Institute of Clinical Excellence committee (NICE Prostate Cancer: NG131) agreed that the 2-year follow-up recommended in the previous prostate cancer guideline was conservative and, based on their expertise, people with no complications and with a stable PSA could be cared for outside of the hospital environment.

NG131 specifies that for people who have a raised PSA and MRI Likert score of 1 or 2, and who have not had a prostate biopsy, PSA blood tests should be repeated at 3 to 6 months and:

  • offer prostate biopsy if there is a strong suspicion of prostate cancer, taking into account their life expectancy and comorbidities
  • discharge the person to primary care if the level of suspicion is low; advise PSA follow-up at 6 months and then every year, and set a PSA level for primary care at which to re-refer based on PSA density or velocity.

The guidance also states that complex cases might need longer contact with hospital-based services (NG 131, 2019).

During 2014-16, TCST and Croydon CCG worked in partnership to develop and test a holistic follow-up service that is catered to the physical and emotional well-being of patients. The pilot improved follow-up processes and shift care from secondary to primary care. In addition to delivering test results closer to home, the service ensured that with the right information, patients were fully supported toward self-management. The original pilot was funded by Prostate Cancer UK and Movember Foundation and compliant in accord with the 2014 version of NICE Prostate Cancer: CG175.

Following the pilot, a London pathway was endorsed by the London Cancer Commissioning Board in 2016. Evaluation of the adapted London pathway shows that:

  • Practice based care is integrated with the holistic management of other long term conditions
  • It offers high levels of patient satisfaction
  • Care is delivered closer to home
  • There is reduced personal cost to patients associated with outpatient appointments (for example travel costs, waiting time for appointments)
  • There is a high level of patient safety
  • There is improved uptake and access to rehabilitation
  • There is reduced specialist input (virtual and face to face);
  • There is no virtual management of test results
  • There is a significant freeing up of outpatient capacity compared with traditional hospital led face to face follow up.
  • The cost per patient is significantly reduced, in comparison to the national secondary care tariff (at the time of the pilot).

Guidance and resources

Conferences, awards and publications

TCST’s pan London primary care pathway has received much attention from across England and overseas since 2015. The team has presented at conferences, a finalist in 2018 Health Services Journal Awards and has published journal articles. These include:

« Back to Personalised cancer care